SCHEMBL6718145

SCHEMBL6718145

NC(C(=O)Nc1cccc2cccnc12)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
MAPT P10636 3/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
KDR P35968 2/20 0.60
TDP1 Q9NUW8 3/20 0.58
POLB P06746 2/20 0.58
CASP3 P42574 1/20 0.58
SENP8 Q96LD8 1/20 0.58
SENP7 Q9BQF6 1/20 0.58
HDAC1 Q13547 2/20 0.57
NLN Q9BYT8 1/20 0.55
KDM4E B2RXH2 2/20 0.54
RECQL P46063 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
TP53 P04637 1/20 0.53
NPC1 O15118 1/20 0.53
ALDH1A1 P00352 1/20 0.53
RAB9A P51151 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL6715719 0.95 MEN1 (0.57) MEN1KMT2AMAPTSMN1; SMN2KDR
SCHEMBL14581452 0.86 HDAC1 (0.69) MEN1KMT2AMAPTSMN1; SMN2KDR
SCHEMBL6719381 0.82 MAPT (0.60) MEN1KMT2AMAPTSMN1; SMN2KDR
SCHEMBL28205773 0.81 KCNQ2 (0.59) MEN1KMT2AMAPTSMN1; SMN2KDR
SCHEMBL28750660 0.80 TDP1 (0.63) MEN1KMT2AMAPTSMN1; SMN2KDR
SCHEMBL28750659 0.80 TDP1 (0.63) MEN1KMT2AMAPTSMN1; SMN2KDR
SCHEMBL3549883 0.79 CYP1A2 (0.71) MEN1KMT2AMAPTSMN1; SMN2KDR
SCHEMBL29152858 0.79 SLC40A1 (0.70) MEN1KMT2AMAPTSMN1; SMN2KDR
SCHEMBL28611344 0.79 KDM4E (0.60) MEN1KMT2AMAPTSMN1; SMN2POLB
SCHEMBL8345384 0.79 KDM4E (0.60) MEN1KMT2AMAPTSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 MEN1 2822/4885KMT2A 1656/4885MAPT 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.